William Blair Issues Positive Outlook for Medpace Earnings

Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) - Research analysts at William Blair boosted their Q3 2025 EPS estimates for Medpace in a research note issued to investors on Wednesday, July 23rd. William Blair analyst M. Smock now expects that the company will post earnings of $3.53 per share for the quarter, up from their prior estimate of $2.95. William Blair currently has a "Market Perform" rating on the stock. The consensus estimate for Medpace's current full-year earnings is $12.29 per share. William Blair also issued estimates for Medpace's Q4 2025 earnings at $3.87 EPS, FY2025 earnings at $14.16 EPS, Q1 2026 earnings at $3.69 EPS, Q2 2026 earnings at $4.15 EPS, Q3 2026 earnings at $3.87 EPS, Q4 2026 earnings at $4.01 EPS and FY2026 earnings at $15.73 EPS.

A number of other equities analysts have also issued reports on the stock. Mizuho boosted their target price on shares of Medpace from $328.00 to $510.00 and gave the stock an "outperform" rating in a research report on Friday. Barclays boosted their target price on shares of Medpace from $300.00 to $450.00 and gave the stock an "equal weight" rating in a research report on Wednesday. Robert W. Baird boosted their target price on shares of Medpace from $313.00 to $490.00 and gave the stock a "neutral" rating in a research report on Wednesday. Cowen lowered shares of Medpace from a "buy" rating to a "sell" rating in a research report on Wednesday. Finally, Deutsche Bank Aktiengesellschaft boosted their target price on shares of Medpace from $270.00 to $430.00 and gave the stock a "hold" rating in a research report on Wednesday. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have given a buy rating to the stock. According to MarketBeat, Medpace presently has an average rating of "Hold" and a consensus target price of $411.10.

Medpace Stock Performance

Shares of Medpace stock traded down $8.19 on Friday, reaching $447.49. The stock had a trading volume of 763,602 shares, compared to its average volume of 683,834. The business's 50-day moving average price is $319.66 and its two-hundred day moving average price is $321.05. Medpace has a fifty-two week low of $250.05 and a fifty-two week high of $501.30. The stock has a market cap of $12.57 billion, a P/E ratio of 33.27, a price-to-earnings-growth ratio of 2.91 and a beta of 1.47.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings data on Monday, July 21st. The company reported $3.10 earnings per share for the quarter, topping analysts' consensus estimates of $3.00 by $0.10. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The business had revenue of $603.31 million during the quarter, compared to analysts' expectations of $537.70 million. During the same period in the previous year, the company earned $2.75 earnings per share. Medpace's revenue for the quarter was up 14.2% on a year-over-year basis.

Institutional Investors Weigh In On Medpace

Several large investors have recently made changes to their positions in the company. Sone Capital Management LLC acquired a new position in Medpace during the 4th quarter worth about $1,318,000. GAMMA Investing LLC raised its position in shares of Medpace by 37.1% in the 1st quarter. GAMMA Investing LLC now owns 307 shares of the company's stock valued at $94,000 after acquiring an additional 83 shares during the period. Orion Portfolio Solutions LLC raised its holdings in Medpace by 347.6% during the 4th quarter. Orion Portfolio Solutions LLC now owns 4,248 shares of the company's stock worth $1,411,000 after buying an additional 3,299 shares during the period. Fundsmith LLP acquired a new stake in Medpace during the 4th quarter worth approximately $42,372,000. Finally, Park Avenue Securities LLC raised its holdings in shares of Medpace by 1.8% in the first quarter. Park Avenue Securities LLC now owns 2,749 shares of the company's stock valued at $838,000 after purchasing an additional 48 shares during the last quarter. Institutional investors own 77.98% of the company's stock.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.